Given the prevalence of Hashimoto’s thyroiditis, which requires thyroid hormone treatment, such a policy change this could significantly increase the workload on the regulatory bodies responsible for evaluating TUE applications and may complicate the approval process. Here, TG is linked to Hashimoto thyroiditis.